Semaglutide Weight Loss Results After 6 Months: What the Data Actually Shows
Medically Reviewed by
Board Certified Endocrinologist
Published
Mar 2, 2026
Last Reviewed
Mar 14, 2026
Sources
5 peer-reviewed
Standard
YMYL / E-E-A-T
Key Takeaways
- •At 6 months (26 weeks), patients in the STEP 1 trial had lost an average of 8–10% of body weight on semaglutide 2.4mg.
- •Final average weight loss at 68 weeks was 14.9% — meaning weight loss continues well past the 6-month mark.
- •Real-world results vary: some patients lose 5%, others 20%+ — individual response depends on dose, adherence, diet, and genetics.
- •If you're at 3 months and haven't seen dramatic results, you likely haven't peaked — maximum weight loss occurs at 12–18 months of continuous treatment.
- •Weight loss stalls are normal at 6–9 months — not a sign the medication stopped working.
The STEP 1 Trial: The Benchmark Everyone Cites
The STEP 1 trial is the most referenced evidence for semaglutide's weight loss efficacy. Published in the New England Journal of Medicine in 2021, it enrolled 1,961 adults with a BMI of 30 or higher who did not have type 2 diabetes. Participants received 2.4mg of semaglutide weekly alongside a reduced-calorie diet and activity counseling. At 68 weeks (roughly 16 months), average weight loss was 14.9% of body weight in the semaglutide group versus 2.4% in the placebo group. Critically, at the 26-week mark — roughly the 6-month point — average weight loss was approximately 8–10% in the active treatment group. The drug keeps working past month six. If you're three months in and feeling discouraged, you likely haven't hit your peak response yet.
Month-by-Month Breakdown: What to Realistically Expect
The titration schedule matters enormously for understanding the timeline. Most prescribers follow a stepwise dose escalation over 16–20 weeks. During weeks 1–4 at 0.25mg, expect mild nausea and 1–2% cumulative weight loss. At the 0.5mg dose (weeks 5–8), nausea often peaks and cumulative loss reaches 2–4%. By weeks 9–12 at 1.0mg, side effects usually stabilize and cumulative loss reaches 4–6%. At the 1.7mg dose (weeks 13–16), some patients experience a brief plateau. By weeks 17–24 at the target 2.4mg dose, most patients tolerate well and cumulative loss reaches 8–12%. A brief plateau at weeks 13–16 is extremely common and causes many people to question the medication — this does not mean it has stopped working.
What 'Average' Doesn't Tell You: The Full Distribution
When researchers report an average of 10% weight loss by 6 months, that smooths over a wide distribution. Approximately 15% of patients lose less than 5% of body weight; about 30% lose 5–9.9%; roughly 28% lose 10–14.9%; 17% lose 15–19.9%; and approximately 10% lose 20% or more. If you've lost 7% at six months, you're squarely in the most common outcome range — not underperforming. The top decile 20%+ results that circulate on social media represent only one in ten patients.
The Variables That Predict Your Outcome
Several factors consistently predict response to semaglutide. Stronger responders tend to have higher baseline BMI, lower fasting insulin at baseline, no prior history of yo-yo dieting, consistent dietary adjustments alongside the medication, and better sleep quality. Weaker responders are more likely to have type 2 diabetes (average losses are roughly 6–8% vs 12–15% in non-diabetic patients), poorly controlled hypothyroidism, use of medications that promote weight gain (antipsychotics, corticosteroids), or high-stress lifestyles with poor sleep. None of these factors are absolute — they shift probabilities rather than determine outcomes.
Real-World Numbers vs. Clinical Trials
Real-world results are typically lower than clinical trial results, and this gap is rarely acknowledged in marketing materials. In clinical trials, participants receive intensive lifestyle support, regular check-ins, and structured guidance. In the real world, most people get a prescription and a handout. A 2024 analysis of electronic health records from over 12,000 patients found an average weight loss of approximately 8.3% at 6 months — meaningful, but lower than the STEP 1 figure. About 28% of patients had discontinued the medication by 6 months, most commonly due to cost or side effects.
What Happens to Your Body Beyond the Scale
The physiological changes at 6 months extend well beyond the number on the scale. Commonly observed by month 6: fasting blood glucose drops 10–20% in pre-diabetic patients; HbA1c reductions of 0.5–1.2% in patients with early type 2 diabetes; blood pressure reductions of 3–5 mmHg systolic; LDL cholesterol may decrease modestly (~5–8%); triglycerides often drop more significantly (~15–25%); liver fat measurably decreases in many patients. These metabolic improvements often happen before you've lost a substantial amount of weight, which is why endocrinologists often frame semaglutide as a metabolic drug first and a weight loss drug second.
Muscle Loss: The Number No One Wants to Talk About
In the STEP trials, body composition analysis showed that roughly 25–40% of total weight lost came from lean mass (muscle and water) rather than fat. This is not unique to semaglutide — it happens with any significant caloric deficit. But it matters because muscle mass affects your long-term metabolic rate and functional capacity. The standard recommendation is to combine semaglutide with resistance training at least 2–3 times per week and ensure adequate protein intake (1.2–1.6g per kg of body weight daily). This doesn't eliminate lean mass loss but substantially reduces it.
Should You Expect Continued Loss After 6 Months?
Yes, generally. The STEP 1 data shows that the rate of weight loss slows after about 20 weeks but continues through approximately weeks 52–60 before reaching a true plateau. Most patients are not at their maximum weight loss by the 6-month mark. A genuine plateau — defined as no weight loss for 8+ weeks despite full dose adherence and dietary compliance — warrants a conversation with your provider about whether the dose is optimized, whether adjunct strategies are needed, or whether a different medication might be more appropriate for your physiology.
Frequently Asked Questions
These answers are for informational purposes only. Always consult your physician for personalized medical advice.
Was this article helpful?
Scientific References & Further Reading
- Wilding JPH et al. — Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM 2021.
- Jastreboff AM et al. — Tirzepatide Once Weekly for the Treatment of Obesity. NEJM 2022.
- FDA Drug Approvals Database — GLP-1 Receptor Agonists. U.S. Food & Drug Administration.
- PubMed — GLP-1 Receptor Agonist Research Index. National Library of Medicine.
- Mayo Clinic — Semaglutide (GLP-1 Agonist): Uses, Side Effects, and Dosing. Mayo Clinic Drug Reference.
This content is produced in accordance with GLP-1 Health's editorial standards and is based on peer-reviewed clinical evidence from the sources cited above. It does not constitute medical advice. Always consult a licensed healthcare provider before starting any medication.
Continue Your GLP-1 Research
Who Qualifies for GLP-1 Injections? BMI Thresholds, Medical Criteria, and the Gray Areas
Getting Started · 10 min read
The Complete GLP-1 Diet: Foods That Work With These Medications (and Foods That Work Against Them)
Nutrition & Diet · 11 min read
Semaglutide Constipation: Natural Remedies That Actually Help
Side Effects · 9 min read
